Company intelligence
CEPI (Coalition for Epidemic Preparedness Innovations)
We want to stop future epidemics by developing new vaccines for a safer world.
About CEPI (Coalition for Epidemic Preparedness Innovations)
CEPI is an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. Central to CEPI’s pandemic-beating plan is the ‘100 Days Mission’ – its goal to develop safe, effective and accessible vaccines against new threats in just 100 days. CEPI is seeking $2.5 billion to execute CEPI 3.0, its 2027-2031 strategy, which will systematically reduce the likelihood, impact and cost of epidemics and pandemics by driving the 100 Days Mission towards an operational reality. Learn more at CEPI.net.
Verified activity
Signals from CEPI (Coalition for Epidemic Preparedness Innovations)
13 published signals
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations) is partnering with Impact Global Health to generate evidence of how biosafety and biosecurity are funded and accounted for in global health R&D settings.
Reported by CEPI (Coalition for Epidemic Preparedness Innovations)
Presence & Recognition
CEPI (Coalition for Epidemic Preparedness Innovations) hosted a pandemic simulation exercise in Jakarta, Indonesia, featuring over 120 experts working across the vaccine and epidemic preparedness research ecosystem to discuss collaboration and leverage Indonesia's pandemic preparedness capability.
Reported by CEPI (Coalition for Epidemic Preparedness Innovations)
Strategy & Corporate Development
CEPI (Coalition for Epidemic Preparedness Innovations) launched CEPI 3.0, a new strategy to shift from reacting to outbreaks to preparing for them.
Reported by Kaleem Ullah Khan
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations) launched the 100 Days Mission, a global goal to develop safe, effective vaccines within 100 days of a new virus emerging.
Reported by Kaleem Ullah Khan
Presence & Recognition
CEPI (Coalition for Epidemic Preparedness Innovations) is hosting a side event at the UN General Assembly High-Level Meeting on Pandemic Prevention, Preparedness and Response in Japan Society, New York on 21 September, 11:30 EST (17:30 CET).
Reported by CEPI (Coalition for Epidemic Preparedness Innovations)
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations) published its latest newsletter highlighting ongoing efforts to close the MPox vaccine access gap, the latest progress in the fight against Bundibugyo ebolavirus, funding for a fifth vaccine candidate, the initiation of another Phase 1 trial, and R&D news.
Reported by CEPI (Coalition for Epidemic Preparedness Innovations)
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations) Disease X Programme Lead Dr Timothy Endy spoke to The BREAK— DOWN about prioritising vaccine development efforts against the highest pandemic potential viral families across the 25 or more known viral families.
Reported by CEPI (Coalition for Epidemic Preparedness Innovations)
Partnerships
CEPI (Coalition for Epidemic Preparedness Innovations) partnered with Egyptian biopharmaceutical company Minapharm Pharmaceuticals to advance an African Bundibugyo ebolavirus vaccine candidate into clinical trials.
Reported by Kaleem Ullah Khan
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations) published its latest newsletter highlighting ongoing efforts to close the MPox vaccine access gap, progress on the Bundibugyo ebolavirus fight, funding for a fifth vaccine candidate, the initiation of a Phase 1 trial, and R&D news.
Reported by Kaleem Ullah Khan
Partnerships
CEPI (Coalition for Epidemic Preparedness Innovations) Executive Director of Process Development and Manufacturing Amadou Sall visited Hilleman Laboratories, a Singapore-based joint venture of biopharmaceutical company MSD and charitable foundation Wellcome Trust, as part of a new partnership to advance the development and manufacturing of Bundibugyo ebolavirus vaccine candidate doses for clinical trials using the recombinant vesicular stomatitis virus (rVSV) platform.
Reported by CEPI (Coalition for Epidemic Preparedness Innovations)
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations) published an explainer from its biosecurity team detailing the role of biosecurity and biosafety in delivering CEPI 3.0 and the 100 Days Mission.
Reported by Kaleem Ullah Khan
Capital & Finance
CEPI (Coalition for Epidemic Preparedness Innovations) is investing US$4.17 million in four research projects to investigate whether existing Ebola vaccines, including Ervebo, can generate immune responses against Bundibugyo ebolavirus.
Reported by Kaleem Ullah Khan
Research & Knowledge
CEPI (Coalition for Epidemic Preparedness Innovations)'s network experts published an explainer blog unpacking how outbreak-ready networks help deliver CEPI 3.0 and the 100 Days Mission.
Reported by Kaleem Ullah Khan